康希諾生物(06185.HK)四價流腦結合疫苗於印尼啟動三期臨床試驗
康希諾生物(06185.HK)公布,旗下四價流行性腦脊髓膜炎(流腦)結合疫苗,於印尼啟動三期臨床試驗,並完成首例受試者入組。該項臨床試驗旨在評價該疫苗產品,在18至55歲人群中接種後的安全性和免疫原性。
公司表示,印尼作為世界第四大人口大國,擁有近3億人口,迫切需要更有效的流腦疫苗接種策略,來實現更強的群體免疫保護效果,同時印尼也是世界上穆斯林人口最多的國家,當地約87%的居民信奉伊斯蘭教,期望穩定供應四價流腦結合疫苗,用於每年去沙特朝聖和朝拜的旅行者接種。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.